41 / 46
A Randomized Phase 2 Study of Cabazitaxel
vs Abiraterone or Enzalutamide in Poor
Prognosis Metastatic Castration-Resistant
Prostate Cancer
Kim N. Chi
1,2
, Sinja Taavitsainen
2
, Nayyer Iqbal
3
, Cristiano Ferrario
4
, Michael Ong
5
, Deepa
Wadhwa
6
, Sebastien J. Hotte
7
, Gregory Lo
8
, Ben Tran
9
, Arun Azad
10
, Lori Wood
11
, Joel R.
Gingerich
12
, Scott North
13
, Carmel J. Pezaro
14
, Dean Ruether
15
, Srikala S. Sridhar
16
, Matti
Annala
2
, Jack Bacon
2
, Alexander W. Wyatt
2
1
BC Cancer - Vancouver Centre,
2
Urologic Sciences, University of British Columbia,
3
Saskatoon Cancer Centre,
4
Jewish
General Hospital ,
5
Ottawa Hospital Cancer Centre,
6
BC Cancer - Kelowna Centre,
7
Juravinski Cancer Centre,
8
Durham
Regional Cancer Centre,
9
Peter MacCallum Cancer Centre,
10
Monash Health
11
QEII Health Sciences Centre,
12
CancerCare
Manitoba,
13
Cross Cancer Institute,
14
Eastern Health,
15
Tom Baker Cancer Centre,
16
Princess Margaret Hospital